361 related articles for article (PubMed ID: 25973911)
21. Integrated differential transcriptome maps of Acute Megakaryoblastic Leukemia (AMKL) in children with or without Down Syndrome (DS).
Pelleri MC; Piovesan A; Caracausi M; Berardi AC; Vitale L; Strippoli P
BMC Med Genomics; 2014 Dec; 7():63. PubMed ID: 25476127
[TBL] [Abstract][Full Text] [Related]
22. Trisomy silencing by XIST normalizes Down syndrome cell pathogenesis demonstrated for hematopoietic defects in vitro.
Chiang JC; Jiang J; Newburger PE; Lawrence JB
Nat Commun; 2018 Dec; 9(1):5180. PubMed ID: 30518921
[TBL] [Abstract][Full Text] [Related]
23. Identification of distinct molecular phenotypes in acute megakaryoblastic leukemia by gene expression profiling.
Bourquin JP; Subramanian A; Langebrake C; Reinhardt D; Bernard O; Ballerini P; Baruchel A; Cavé H; Dastugue N; Hasle H; Kaspers GL; Lessard M; Michaux L; Vyas P; van Wering E; Zwaan CM; Golub TR; Orkin SH
Proc Natl Acad Sci U S A; 2006 Feb; 103(9):3339-44. PubMed ID: 16492768
[TBL] [Abstract][Full Text] [Related]
24. The role of the proto-oncogene ETS2 in acute megakaryocytic leukemia biology and therapy.
Ge Y; LaFiura KM; Dombkowski AA; Chen Q; Payton SG; Buck SA; Salagrama S; Diakiw AE; Matherly LH; Taub JW
Leukemia; 2008 Mar; 22(3):521-9. PubMed ID: 18094719
[TBL] [Abstract][Full Text] [Related]
25. Are GATA1 mutations occurring at random in Down syndrome transient leukemia?
Satgé D
Med Hypotheses; 2014 Aug; 83(2):154-9. PubMed ID: 24880866
[TBL] [Abstract][Full Text] [Related]
26. Transposon mutagenesis reveals cooperation of ETS family transcription factors with signaling pathways in erythro-megakaryocytic leukemia.
Tang JZ; Carmichael CL; Shi W; Metcalf D; Ng AP; Hyland CD; Jenkins NA; Copeland NG; Howell VM; Zhao ZJ; Smyth GK; Kile BT; Alexander WS
Proc Natl Acad Sci U S A; 2013 Apr; 110(15):6091-6. PubMed ID: 23533276
[TBL] [Abstract][Full Text] [Related]
27. Mapping the cellular origin and early evolution of leukemia in Down syndrome.
Wagenblast E; Araújo J; Gan OI; Cutting SK; Murison A; Krivdova G; Azkanaz M; McLeod JL; Smith SA; Gratton BA; Marhon SA; Gabra M; Medeiros JJF; Manteghi S; Chen J; Chan-Seng-Yue M; Garcia-Prat L; Salmena L; De Carvalho DD; Abelson S; Abdelhaleem M; Chong K; Roifman M; Shannon P; Wang JCY; Hitzler JK; Chitayat D; Dick JE; Lechman ER
Science; 2021 Jul; 373(6551):. PubMed ID: 34244384
[TBL] [Abstract][Full Text] [Related]
28. Overexpression of ERG in cord blood progenitors promotes expansion and recapitulates molecular signatures of high ERG leukemias.
Tursky ML; Beck D; Thoms JA; Huang Y; Kumari A; Unnikrishnan A; Knezevic K; Evans K; Richards LA; Lee E; Morris J; Goldberg L; Izraeli S; Wong JW; Olivier J; Lock RB; MacKenzie KL; Pimanda JE
Leukemia; 2015 Apr; 29(4):819-27. PubMed ID: 25306899
[TBL] [Abstract][Full Text] [Related]
29. Increased dosage of the chromosome 21 ortholog Dyrk1a promotes megakaryoblastic leukemia in a murine model of Down syndrome.
Malinge S; Bliss-Moreau M; Kirsammer G; Diebold L; Chlon T; Gurbuxani S; Crispino JD
J Clin Invest; 2012 Mar; 122(3):948-62. PubMed ID: 22354171
[TBL] [Abstract][Full Text] [Related]
30. Developmental stage-selective effect of somatically mutated leukemogenic transcription factor GATA1.
Li Z; Godinho FJ; Klusmann JH; Garriga-Canut M; Yu C; Orkin SH
Nat Genet; 2005 Jun; 37(6):613-9. PubMed ID: 15895080
[TBL] [Abstract][Full Text] [Related]
31. Tumour angiogenesis is reduced in the Tc1 mouse model of Down's syndrome.
Reynolds LE; Watson AR; Baker M; Jones TA; D'Amico G; Robinson SD; Joffre C; Garrido-Urbani S; Rodriguez-Manzaneque JC; Martino-Echarri E; Aurrand-Lions M; Sheer D; Dagna-Bricarelli F; Nizetic D; McCabe CJ; Turnell AS; Kermorgant S; Imhof BA; Adams R; Fisher EM; Tybulewicz VL; Hart IR; Hodivala-Dilke KM
Nature; 2010 Jun; 465(7299):813-7. PubMed ID: 20535211
[TBL] [Abstract][Full Text] [Related]
32. Recent insights into the mechanisms of myeloid leukemogenesis in Down syndrome.
Gurbuxani S; Vyas P; Crispino JD
Blood; 2004 Jan; 103(2):399-406. PubMed ID: 14512321
[TBL] [Abstract][Full Text] [Related]
33. Acute myeloid leukemia: a central role for the ETS factor ERG.
Martens JH
Int J Biochem Cell Biol; 2011 Oct; 43(10):1413-6. PubMed ID: 21664289
[TBL] [Abstract][Full Text] [Related]
34. Frequent mutations in the GATA-1 gene in the transient myeloproliferative disorder of Down syndrome.
Xu G; Nagano M; Kanezaki R; Toki T; Hayashi Y; Taketani T; Taki T; Mitui T; Koike K; Kato K; Imaizumi M; Sekine I; Ikeda Y; Hanada R; Sako M; Kudo K; Kojima S; Ohneda O; Yamamoto M; Ito E
Blood; 2003 Oct; 102(8):2960-8. PubMed ID: 12816863
[TBL] [Abstract][Full Text] [Related]
35. Acute megakaryoblastic leukaemia (AMKL) and transient myeloproliferative disorder (TMD) in Down syndrome: a multi-step model of myeloid leukaemogenesis.
Roy A; Roberts I; Norton A; Vyas P
Br J Haematol; 2009 Oct; 147(1):3-12. PubMed ID: 19594743
[TBL] [Abstract][Full Text] [Related]
36. Morphologic and GATA1 sequencing analysis of hematopoiesis in fetuses with trisomy 21.
Hoeller S; Bihl MP; Tzankov A; Chaffard R; Hirschmann P; Miny P; Kühne T; Bruder E
Hum Pathol; 2014 May; 45(5):1003-9. PubMed ID: 24746204
[TBL] [Abstract][Full Text] [Related]
37. Down myeloid disorders: a paradigm for childhood preleukaemia and leukaemia and insights into normal megakaryopoiesis.
Vyas P; Roberts I
Early Hum Dev; 2006 Dec; 82(12):767-73. PubMed ID: 17064858
[TBL] [Abstract][Full Text] [Related]
38. Mouse models of Down syndrome: gene content and consequences.
Gupta M; Dhanasekaran AR; Gardiner KJ
Mamm Genome; 2016 Dec; 27(11-12):538-555. PubMed ID: 27538963
[TBL] [Abstract][Full Text] [Related]
39. Stepwise GATA1 and SMC3 mutations alter megakaryocyte differentiation in a Down syndrome leukemia model.
Arkoun B; Robert E; Boudia F; Mazzi S; Dufour V; Siret A; Mammasse Y; Aid Z; Vieira M; Imanci A; Aglave M; Cambot M; Petermann R; Souquere S; Rameau P; Catelain C; Diot R; Tachdjian G; Hermine O; Droin N; Debili N; Plo I; Malinge S; Soler E; Raslova H; Mercher T; Vainchenker W
J Clin Invest; 2022 Jul; 132(14):. PubMed ID: 35587378
[TBL] [Abstract][Full Text] [Related]
40. Modeling Down Syndrome Myeloid Leukemia by Sequential Introduction of
Barwe SP; Sebastian A; Sidhu I; Kolb EA; Gopalakrishnapillai A
Cells; 2022 Feb; 11(4):. PubMed ID: 35203280
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
